Skip to content
DataLookout
Menu

MorningSunNCT05207670

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 2 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 46 versions: 38 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 54 words
    • Primary completion pushed from Jul 31, 2027 to Oct 1, 2027
    • Study completion pushed from Jul 31, 2027 to Oct 29, 2027
    • Site details revised at 4 of 39 sites
  2. Notable Primary and study completion moved earlier from Jul 31, 2028 to Jul 31, 2027v44
  3. Minor Study sites revised (39)v42
  4. Minor Site details revised at 1 of 39 sitesv40
  5. Minor Study sites: 41 to 39v39
Show 32 earlier versionsHide 32 earlier versions
  1. Minor Enrollment target: estimated 345 to confirmed 320v38
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 58 to 41
    v37
  3. Minor Site details revised at 3 of 58 sitesv36
  4. Minor Site details revised at 2 of 58 sitesv34
  5. Minor Study sites revised (58)v33
  6. Minor Study sites revised (58)v32
  7. Minor Study sites: 57 to 58v31
  8. Minor Study sites revised (57)v30
  9. Minor Study sites revised (57)v29
  10. Minor Site details revised at 3 of 57 sitesv26
  11. Minor Study sites: 56 to 57v25
  12. Minor Study sites: 54 to 56v23
  13. Minor Study sites: 53 to 54v22
  14. Minor Site details revised at 1 of 53 sitesv21
  15. Minor Study sites: 48 to 53v19
  16. Minor Study sites: 46 to 48v18
  17. Minor Study sites: 44 to 46v17
  18. Notable Primary and study completion dates: Dec 17, 2026 to Jul 31, 2028v16 Show 4 more changesShow less
    • Eligibility criteria expanded, about 131 words
    • Enrollment target: 275 to 345
    • Study sites: 39 to 44
    • Secondary endpoints: 9 to 10
  19. Minor Study sites: 37 to 39v15
  20. Minor Site details revised at 1 of 37 sitesv14
  21. Minor Study sites: 27 to 37v13
  22. Minor Study sites: 25 to 27v12
  23. Minor Study sites: 22 to 25v11
  24. Minor Study sites: 20 to 22v10
  25. Minor Study sites: 19 to 20v9
  26. Notable Eligibility criteria expanded, about 1 word
    • Study sites: 18 to 19
    v8
  27. Minor Study sites: 14 to 18v7
  28. Notable Eligibility criteria expanded, about 17 words
    • Study sites: 10 to 14
    v6
  29. Minor Study sites: 5 to 10v5
  30. Minor Study sites: 2 to 5v4
  31. Minor Start date changed from estimate of Feb 15, 2022 to Feb 1, 2022v3
  32. Minor Study sites: 1 to 2
    • Start date: Jan 21, 2022 to Feb 15, 2022
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free survival (PFS) rate at 24 months after the first study treatment (Cohorts A1, A2, and B)
Timeframe: From the first study treatment to the first occurrence of disease progression, relapse, or death from any cause, whichever occurs first, as determined by the investigator according to Lugano Criteria 2014 (minimum 2 years)
Objective response rate (ORR), defined as the proportion of participants with a complete metabolic response (CMR) or partial response (PR), as determined by the investigator according to the Lugano Criteria 2014 (Cohorts C, D, and E)
Timeframe: Cycles 4, 8, 12 and 17 (cycle length=21 days)

Secondary (10)

Overall survival (OS) (all cohorts)
ORR, defined as the proportion pf participants with a CMR or PR, as determined by the investigator according to the Lugano Criteria 2014 (Cohorts A1, A2, and B)
Time to response (TTR) (all cohorts)
Duration of response (DOR) (all cohorts)
DOR for participants with best response of CMR (all cohorts)
Show 5 moreShow less
Duration of complete response (DoCR) (all cohorts)
Time to next treatment (TTNT) (all cohorts)
PFS (all cohorts)
Percentage of participants with adverse events (AEs) (all cohorts)
Serum concentration of mosunetuzumab (all cohorts)

Arms and interventions

Cohort AExperimental

Participants with high tumor burden with untreated follicular lymphoma (FL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first. Participants that achieve complete or partial metabolic response will have the option of receiving maintenance therapy with mosunetuzumab every 8 weeks for 1 year.

Cohort BExperimental

Elderly participants with untreated diffuse large B-cell lymphoma (DLBCL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.

Cohort CExperimental

Participants with untreated marginal zone lymphoma (MZL) will receive SC mosunetuzumab monotherapy for up to 17 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.

Cohort DExperimental

Participants with relapsed or refractory (R/R) mantle cell lymphoma (MCL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.

Cohort EExperimental

Participants with R/R Richter's transformation (RT), or R/R transformed follicular lymphoma (tFL) will receive SC mosunetuzumab monotherapy for up to 34 cycles or until radiographic disease progression, study discontinuation, or death, whichever occurs first.

Drugs: Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab

Sites

39 sites in 1 country